RMD - ResMed Inc. News

Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price

defenseworld.net

Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD

Canada Pension Plan Investment Board bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farre

defenseworld.net

228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.

American Capital Management Inc. bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the unde

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

247wallst.com

The IRS Makes You Sell Whether the Market Is Up or Down. These 3 ETFs Fund the RMD Without Touching

Turning 73 changes the math on your retirement account. The IRS no longer lets your traditional IRA

Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutra

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron T

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health techno

defenseworld.net

87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co

Avalon Trust Co bought a new stake in ResMed Inc. (NYSE: RMD) during the undefined quarter, accordin

seekingalpha.com

Dividend Champion, Contender, And Challenger Highlights: Week August 16

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies

marketbeat.com

ResMed Q4 Earnings Call Highlights

ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8%

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises t

Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance tr

reuters.com

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fisc

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price

Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers th

Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea

gurufocus.com

ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic Portfolio S

Revenue: Group revenue for Q4 FY2026 was $1.5 billion, a 9% headline increase and 8% growth on a con

seekingalpha.com

ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

ResMed (RMD) Q4 Earnings and Revenues Top Estimates

ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estima

ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus es

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP dil

What to Expect From These 2 MedTech Stocks This Earnings Season?

Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, infla

Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond th

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Resmed's Q4 Earnings on Deck: What's in Store for the Stock?

RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and d

Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220

Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price

Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235

Citigroup analyst Laura Sutcliffe downgrades ResMed (NYSE:RMD) from Buy to Neutral and lowers the

Jefferies Maintains Hold on ResMed, Lowers Price Target to $225

Jefferies analyst Matthew Taylor maintains ResMed (NYSE:RMD) with a Hold and lowers the price tar

ResMed Analyst Backs Portfolio Reset

ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh ne

RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and lowers the p

Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers th

ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027

On July 7, 2026, ResMed Inc. (the "Company" or "Resmed") issued a press release anno

Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266

Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the pri

Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis

Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrad

Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230

Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight

ResMed Acquires Sleep-Related Wearables Developer Noctrix Health From Angelini Industries For $340M

Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in compani

Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now

Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the p

Transcript: ResMed Q3 2026 Earnings Conference Call

Resmed Appoints Aaron Bloomer CFO, Succeeding Brett Sandercock

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and

ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus es